Hemab Therapeutics has raised a $135M Series B to develop therapies for health conditions that lead to blood clotting issues.
The company has raised $190M since its inception in 2017.
- The company is in the clinical trial process for therapies that aim to help patients with several diseases, such as:
- Factor VII Deficiency,
- Bernard Soulier Syndrome,
- Von Willebrand Disease,
- Hereditary Hemorrhagic Telangiectasia
- Access Biotechnology led the Series B funding round, with participation from Deep Track Capital, Avoro Ventures, Invus, Rock Springs Capital, Maj Invest Equity, Novo Holdings, RA Capital Management, and HealthCap.
- Hemab aims to use the funding to boost its studies on developing therapies for Glanzmann Thrombasthenia and von Willebrand Disease.
- The company is based in Denmark and Boston, Massachusetts.
